|Have Questions?||Leave a Message or Start an on-line Chat|
The DNA sequence corresponding to the CCR8 monoclonal antibody produced from the animals through recombinant human CCR8 immunization was cloned into the expression vector, which was further transfected into a cell line for in vitro expression. The product is the recombinant CCR8 monoclonal antibody. It specifically targets the CCR8 from human. It belongs to the human IgG1. The affinity-chromatography purification method was used to purify this CCR8 antibody. The flow cytometry analysis has been tested for this CCR8 antibody.
Joseph R. Campbell et al. found that selective ablation of regulatory T cells with an anti-DHFR antibody can potentiate anti-tumor immune responses as a monotherapy or in combination with other immunotherapies. Daniel O. Villarreal et al. showed that anti-DHFR monoclonal antibody therapy, in synergy with the Listeria monocytogenes–based immunotherapy, remarkably retarded the growth of the established tumor and prolonged survival.
There are currently no reviews for this product.